NASDAQ 100 % ()
FTSE 100 % ()
S&P 500 % ()
BTC/USD % ()
XRP/USD % ()
ETH/USD % ()
GBP/USD % ()
GOLD % ()
SILVER % ()

SVRA

Savara Inc. Nasdaq Global Select
$1.73
Open: $1.84 High: $1.87 Low: $1.695 Close: $1.71
Range: 2021-03-02 - 2021-03-03
Volume: 583,467
Market: Open
Powered by Finage Stock APIDelayed data
SVRA
Savara Inc. 6836 Bee Cave Road Austin TX, 78746 http://www.savarapharma.com
Savara Inc is a pharmaceutical company. The company develops novel therapies for the treatment of serious or life-threatening rare respiratory diseases.
  • CEO: Roberto Neville
  • Employees: 24
  • Sector: Healthcare
  • Industry: Biotechnology
SVRA News
Latest news about the SVRA
  • Is the Options Market Predicting a Spike in Savara (SVRA) Stock?

    Investors need to pay close attention to Savara (SVRA) stock based on the movements in the options market lately.

    View More →
  • Is Savara (NASDAQ:SVRA) Using Too Much Debt?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...

    View More →
  • Is SVRA A Good Stock To Buy Now?

    The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. Most hedge fund investors experienced strong gains on the back of a strong market performance, which certainly propelled them to adjust their equity holdings so as […]

    View More →
  • Savara Provides Pipeline and Business Update

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company’s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial.

    View More →
  • Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara Management will participate in virtual fireside chats at the following investor healthcare conferences:

    View More →
  • Savara to Present at the Jefferies Virtual London Healthcare Conference

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Matthew Pauls, Chairman and Interim CEO, will be presenting at the Jefferies Virtual London Healthcare Conference on Wednesday, November 18, 2020 at 2:55 PM EST/11:55 AM PST.

    View More →
  • Savara Reports Third Quarter 2020 Financial Results and Provides Business Update

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the third quarter ending September 30, 2020 and provided a business update.

    View More →
  • Savara Announces Senior Management Changes

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Rob Neville has resigned as the Company’s Chief Executive Officer (CEO) and from the Board of Directors, effective immediately, to pursue other opportunities. The Company’s Board of Directors has appointed Matthew Pauls as Chairman and Interim CEO. Mr. Pauls has served as a member of Savara’s Board of Directors since 2017 and is a seasoned biopharmaceutical leader with extensive experience in the rare disease sector. Taneli Jouhikainen, President and Chief Business Officer, has also resigned to pursue other opportunities.

    View More →
  • Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the H.C. Wainwright Annual Investment Conference on Wednesday, September 16, 2020 at 3:00 PM EDT/12:00 PM PDT.

    View More →
  • Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that results from the Phase 3 IMPALA study were published online in NEJM. The manuscript, titled "Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis," appears in the September 7, 2020 online version of the publication and can be found at www.nejm.org.

    View More →
  • Savara to Stop Study on Molgradex for NTM Lung Infection

    Savara (SVRA) to halt the ENCORE study on its lead candidate Molgradex, which was meant to treat nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis.

    View More →
  • The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study

    Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) * Akouos Inc (NASDAQ: AKUS) * FibroGen Inc (NASDAQ: FGEN)(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) * Generation Bio Co (NASDAQ: GBIO) * Immunovant Inc (NASDAQ: IMVT) * Sutro Biopharma Inc (NASDAQ: STRO) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) * Akebia Therapeutics Inc (NASDAQ: AKBA) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) * Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Homology Medicines Inc (NASDAQ: FIXX) * Immatics NV (NASDAQ: IMTX) * Interpace Biosciences Inc (NASDAQ: IDXG) * Jaguar Health Inc (NASDAQ: JAGX) * Legend Biotech Corp (NASDAQ: LEGN) * Monopar Therapeutics Inc (NASDAQ: MNPR) * NanoVibronix Inc (NASDAQ: NAOV) * Odonate Therapeutics Inc (NASDAQ: ODT) * RA Medical Systems Inc (NYSE: RMED) * Recro Pharma Inc (NASDAQ: REPH) * Rockwell Medical Inc (NASDAQ: RMTI) * Soliton Inc (NASDAQ: SOLY) * Sun BioPharma, Inc. (NASDAQ: SNBP) * Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) * Teligent Inc(NASDAQ: TLGT)Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA DatesStocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity. The approval expands the label of once-weekly Trulicity to include 3 mg and 4.5 mg doses based on data from the AWARD-11 study. The phase 3 trial showed the additional doses led to further benefits in A1C and body weight reduction when compared to Trulicity 1.5 mg, Lilly said.Trulicity fetched about 22.5% of Lilly's total revenues in the recently reported second quarter and saw growth of 20% year-over-year.Lilly said the two additional doses will be available in the U.S. in late September.OraSure's RNA Collection Device Gets EUA To Be Used In COVID-19 Test OraSure Technologies, Inc. (NASDAQ: OSUR) said its ORAcollect*RNA (OR-100) collection device was included along with other devices in the FDA emergency use authorization, or EUA, granted to MiraDx Inc., a Los Angeles-based molecular genetics company.MiraDx will utilize the device to collect oropharyngeal samples in its COVID-19 testing program for essential workers and first responders to help prevent the spread of COVID-19, OraSure said.The stock added 4.57% to $11.21 in after-hours trading.AbbVie To License I-Mab's Cancer Drug For Up to $1.94B AbbVie Inc (NYSE: ABBV) and I-Mab ADR (NASDAQ: IMAB) said they have signed a broad, global collaboration agreement for the development and commercialization of lemzoparlimab, an anti-CD47 monoclonal antibody internally discovered and developed by I-Mab for the treatment of multiple cancers. In addition, the two partners have the potential to expand the collaboration to additional transformative therapies.Under the terms of the agreement, AbbVie will pay I-Mab $180 million in an upfront payment to exclusively license lemzoparlimab, along with $20 million in a milestone payment based on the Phase 1 results, for a total of $200 million. In addition, I-Mab will be eligible to receive up to $1.74 billion in success-based milestone payments, of which $840 million are based on clinical development and regulatory approval milestones, with the remainder based on commercial milestonesSeparately, I-Mab said it has entered into definitive subscription agreements with a consortium of institutional investors led by Hillhouse Capital to raise approximately $418 million through a private placement.View more earnings on IBBI-Mab shares were adding 9.73% to $39.25 in pre-market trading, while AbbVie was up 1.23% to $93.Savara Discontinues Mid-stage Cystic Fibrosis Study Due to COVID-19 and Availability of Rival Drug Savara Inc (NASDAQ: SVRA) said it has decided to discontinue the ENCORE Phase 2a exploratory study, that is evaluating Molgradex for the treatment of nontuberculous mycobacterial lung infection in people living with cystic fibrosis.Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor.The company attributed the decision to discontinue to the impact of COVID-19 on patient recruitment and continued participation in the study as well as the availability of Vertex Pharmaceuticals Incorporated's (NASDAQ: VRTX) new triple-combination CFTR modulator that has become a preferred treatment option for many cystic fibrosis patients.Savara shares fell 12.41% to $1.20 in after-hours trading.Roche's Test to Detect SARS-CoV-2 and Influenza A/B Viruses Gets EUA Roche Holdings AG Basel (OTC: RHHBY) said its cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systems has received EUA from the FDA This test is intended for the simultaneous qualitative detection and differentiation of SARS-CoV-2, Influenza A and Influenza B in patients suspected by their healthcare provider of having respiratory viral infection consistent with COVID-19, Roche saidPuma's Licensing Partner Makes Regulatory Submission Seeking Label Expansion for Breast Cancer Drug Canadian specialty pharma Knight Therapeutics said it has submitted a supplement to a new drug submission to the Canadian regulatory agency to get a label expansion for Puma Biotechnology Inc's (NASDAQ: PBYI) breast cancer drug Nerlynx. Knight had in-licensed the drug to market it in Canada.Nerlynx was originally approved in Canada in July 2019 as an extended adjuvant treatment of women with early-stage HER2-overexpressed/amplified breast cancer within one year after completion of Roche's Herceptin-based adjuvant therapy.The company now seeks to get approval for the drug as a treatment option for metastatic breast cancer.Earnings Medical device company Cooper Companies Inc (NYSE: COO) reported third-quarter revenues of $578.2 million, down 15% year-over-year, and non-GAAP EPS of $2.28, down 30%. The EPS, however, was ahead of the $1.52-per share consensus estimate.For the fourth quarter, the company expects non-GAAP EPS of $3 to $3.20 on revenues of $665 million to $693 million. Analysts, on average, estimate EPS of $2.82 on revenues of $661.73 million.In after-hours trading, the stock added 3.65% to $318.Offerings Obseva SA (NASDAQ: OBSV) announced the pricing for its underwritten public offering of common shares, which would fetch the company $20 million in gross proceeds. The company also said a concurrent private placement priced at-the-market of common shares and 15-month purchase warrants would potentially raise an additional $23.9 million.See more from Benzinga * The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    View More →
  • Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF)

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the decision to discontinue ENCORE, a 48-week, open-label, non-controlled Phase 2a exploratory clinical study of Molgradex for the treatment of nontuberculous mycobacterial (NTM) lung infection in people living with cystic fibrosis (CF). Molgradex, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF), was also evaluated for the treatment of NTM in non-CF patients in the Phase 2a OPTIMA study that completed in March 2020.

    View More →
  • Savara Enters Oversold Territory

    Savara has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

    View More →
  • Savara Reports Second Quarter 2020 Financial Results and Provides Business Update

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.

    View More →
  • Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that the Company's Chief Executive Officer, Rob Neville, will present at the virtual Canaccord Genuity Global Growth Conference on Wednesday, August 12, 2020 at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time.

    View More →
  • Savara to Report Second Quarter 2020 Financial Results and Provide Business Update

    Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report second quarter 2020 financial results and provide a business update on Thursday, August 6, 2020. Savara management will host a conference call/webcast at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).

    View More →
  • Were Hedge Funds Right About Souring On Savara, Inc. (SVRA)?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional investors have to conduct complex analyses, spend many resources and use tools that are not […]

    View More →
  • Savara to Present at the Jefferies Virtual Healthcare Conference

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced that Savara management will be presenting at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 10:30 a.m. ET / 7:30 a.m. PT.

    View More →
  • Savara Announces Change of Date for 2020 Annual Meeting of Stockholders

    Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced a change in the date, time, and format of its 2020 Annual Meeting of Stockholders due to public health and safety concerns related to the COVID-19 pandemic and in the interest of the health and well-being of stockholders and other meeting participants. The Annual Meeting will now be held in a virtual-only format by means of a live audio webcast at 3:00 p.m. CDT on Friday, May 29, 2020, instead of the location, time, and date previously disclosed in the proxy materials filed with the Securities and Exchange Commission on April 15, 2020. Stockholders will not be able to attend the Annual Meeting in person.

    View More →